Pilot RCT of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Ankle and Foot Pain (PREPLANS)
Primary Purpose
CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT
Status
Completed
Phase
Early Phase 1
Locations
Canada
Study Type
Interventional
Intervention
0.9% saline
0.25% bupivacaine hydrochloride injectable suspension USP
4mg/cc methylprednisolone acetate injectable suspension USP
Sponsored by
About this trial
This is an interventional treatment trial for CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT focused on measuring ankle pain, foot pain, methylprednisolone, neuropathic pain
Eligibility Criteria
Inclusion Criteria:
- Pain in foot in neuro-anatomically congruent location following trauma (including surgery) for more than three months
- Physician-reported DN4 scoring confirming neuropathic pain (score > 3/10)
- Average intensity of pain more than 3/10 on numerical rating score
- Failed trial of appropriate doses of first line medications for neuropathic pain (anticonvulsants and/or antidepressants) for six weeks
Exclusion Criteria:
- Age < 18 or age ≥ 80 years
- Perineural or intra-articular steroid injections in the last 6 months
- Allergy to local anesthetics and/or steroids
- Ongoing litigation issues related to the patient's pain
- Pregnancy
- Coagulopathy or systemic infection
- Peripheral neuropathy or myopathy, central neuropathic pain (e.g. post-stroke pain)
- Infection in the ankle or foot
- An unstable medical or psychiatric condition
- Significant catastrophizing as indicated by pain catastrophizing scale (PCS) score equal to or more than 30/52
Sites / Locations
- Toronto Western Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
0.9% saline (salt water)
local anesthetic (freezing)
local anesthetic (freezing) and steroid
Arm Description
0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
Outcomes
Primary Outcome Measures
Enrollment and retention of participants (SEE DESCRIPTION)
Factors considered in assessment: Enrolling at least 75% of eligible patients, enrolling at least 9 patients monthly, retention till study end of at least 90% of participants
Secondary Outcome Measures
Central tendency (mean) and spread (standard deviation) of Numerical Rating Score (NRS) ratings of Foot and Ankle pain
Change in scores of Pain Catastrophizing Score (PCS)
Change in scores of Dolores Neuropathique (DN4)
Change in scores of Neuropathic Pain Symptom Inventory (NPSI)
Change in scores of anxiety component scores on the Hospital Anxiety and Depression Scale (HADS)
Change in scores of depression scores on the Patient Health Questionnaire-9 (PHQ-9)
Change in scores of Brief Pain Inventory interference with activities (BPI-I)
Change in scores of Short Form-12 (SF-12)
Change in scores of Lower Extremity Function Score (LEFS)
Evaluate the impact of study interventions on requirement for opioids (measured as average daily oral morphine equivalents in mg) and neuropathic medications (average daily doses of gabapentin and/or amitriptyline in mg)
Change in pre- and post-intervention levels of blood glucose and blood pressure
Measure incidence of infections at the injection site, skin discoloration or atrophy at the injection site, fractures, and evidence of myopathy
Full Information
NCT ID
NCT02680548
First Posted
December 11, 2015
Last Updated
April 30, 2018
Sponsor
University Health Network, Toronto
1. Study Identification
Unique Protocol Identification Number
NCT02680548
Brief Title
Pilot RCT of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Ankle and Foot Pain
Acronym
PREPLANS
Official Title
A Pilot Randomized Controlled Trial of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Neuropathic Pain in the Ankle and the Foot: The PREPLAN Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
November 2015 (undefined)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
December 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Health Network, Toronto
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Injections of local anesthetics (freezing) and steroids are often performed around injured nerves in individuals with nerve injury-related pain. The current standard of medical care is to inject a combination of local anesthetics and steroids around injured nerves, but there is no proof that this is better than injecting only local anesthetic, or even just sterile salt water. There is evidence to believe that injection of local anesthetic (without the steroid) can calm the injured nerve, and provide pain relief from a few days up to a few months. Injection of sterile salt water also has the potential to provide pain relief by breaking scar tissue around the nerve, thereby relieving compression. The aim of this study is to compare pain relief and possible adverse effects from these three different treatments for foot and ankle nerve pain relief.
All 30 participants will be recruited over 9 months from the Altum Health clinic at Toronto Western Hospital. 10 participants will be randomly assigned to each treatment. Each patient will receive 3 injections over 3 weeks or so. Participants will have an in-clinic follow-up at 1 month after the last injection, and a phone follow-up 3 months after the last injection.
This is a small-scale study, and information obtained from this study will help in planning and conduct of a larger study with more participants. The larger study will help determine the best possible option for injection in patients with nerve-related injury pain.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT
Keywords
ankle pain, foot pain, methylprednisolone, neuropathic pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
0.9% saline (salt water)
Arm Type
Active Comparator
Arm Description
0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
Arm Title
local anesthetic (freezing)
Arm Type
Active Comparator
Arm Description
0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
Arm Title
local anesthetic (freezing) and steroid
Arm Type
Active Comparator
Arm Description
0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
Intervention Type
Drug
Intervention Name(s)
0.9% saline
Other Intervention Name(s)
Salt Water
Intervention Type
Drug
Intervention Name(s)
0.25% bupivacaine hydrochloride injectable suspension USP
Other Intervention Name(s)
Marcaine
Intervention Type
Drug
Intervention Name(s)
4mg/cc methylprednisolone acetate injectable suspension USP
Other Intervention Name(s)
Depo-Medrol
Primary Outcome Measure Information:
Title
Enrollment and retention of participants (SEE DESCRIPTION)
Description
Factors considered in assessment: Enrolling at least 75% of eligible patients, enrolling at least 9 patients monthly, retention till study end of at least 90% of participants
Time Frame
At end of study (1 year)
Secondary Outcome Measure Information:
Title
Central tendency (mean) and spread (standard deviation) of Numerical Rating Score (NRS) ratings of Foot and Ankle pain
Time Frame
At 1-month and 3-months post-intervention
Title
Change in scores of Pain Catastrophizing Score (PCS)
Time Frame
Baseline and at 1-month post-intervention
Title
Change in scores of Dolores Neuropathique (DN4)
Time Frame
Baseline and at 1-month post-intervention
Title
Change in scores of Neuropathic Pain Symptom Inventory (NPSI)
Time Frame
Baseline and at 1-month post-intervention
Title
Change in scores of anxiety component scores on the Hospital Anxiety and Depression Scale (HADS)
Time Frame
Baseline and at 1-month post-intervention
Title
Change in scores of depression scores on the Patient Health Questionnaire-9 (PHQ-9)
Time Frame
Baseline and at 1-month post-intervention
Title
Change in scores of Brief Pain Inventory interference with activities (BPI-I)
Time Frame
Baseline and at 1-month post-intervention
Title
Change in scores of Short Form-12 (SF-12)
Time Frame
Baseline and at 1-month post-intervention
Title
Change in scores of Lower Extremity Function Score (LEFS)
Time Frame
Baseline and at 1-month post-intervention
Title
Evaluate the impact of study interventions on requirement for opioids (measured as average daily oral morphine equivalents in mg) and neuropathic medications (average daily doses of gabapentin and/or amitriptyline in mg)
Time Frame
At end of study (1 year)
Title
Change in pre- and post-intervention levels of blood glucose and blood pressure
Time Frame
Baseline and at 1-month post-intervention
Title
Measure incidence of infections at the injection site, skin discoloration or atrophy at the injection site, fractures, and evidence of myopathy
Time Frame
Baseline and at 1-month post-intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pain in foot in neuro-anatomically congruent location following trauma (including surgery) for more than three months
Physician-reported DN4 scoring confirming neuropathic pain (score > 3/10)
Average intensity of pain more than 3/10 on numerical rating score
Failed trial of appropriate doses of first line medications for neuropathic pain (anticonvulsants and/or antidepressants) for six weeks
Exclusion Criteria:
Age < 18 or age ≥ 80 years
Perineural or intra-articular steroid injections in the last 6 months
Allergy to local anesthetics and/or steroids
Ongoing litigation issues related to the patient's pain
Pregnancy
Coagulopathy or systemic infection
Peripheral neuropathy or myopathy, central neuropathic pain (e.g. post-stroke pain)
Infection in the ankle or foot
An unstable medical or psychiatric condition
Significant catastrophizing as indicated by pain catastrophizing scale (PCS) score equal to or more than 30/52
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anuj Bhatia, MD, FRCPC
Organizational Affiliation
University Health Network, Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
Toronto Western Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T2S8
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27334885
Citation
Bhatia A, Bril V, Brull RT, Perruccio A, Wijeysundera D, Alvi S, Lau J, Gandhi R, Mahomed N, Davis AM. Study protocol for a pilot, randomised, double-blinded, placebo controlled trial of perineural local anaesthetics and steroids for chronic post-traumatic neuropathic pain in the ankle and foot: the PREPLANS study. BMJ Open. 2016 Jun 22;6(6):e012293. doi: 10.1136/bmjopen-2016-012293. Erratum In: BMJ Open. 2016 Jul 04;6(7):e012293corr1.
Results Reference
derived
Learn more about this trial
Pilot RCT of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Ankle and Foot Pain
We'll reach out to this number within 24 hrs